Candel Therapeutics, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:CADL) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -8.62 M-8.89 M-10.24 M-10.57 M-18.04 M -47.73 M Cash from investing activities -3 000-31 K-117 K-409 K-675 K -1.23 M Cash from financing activities -1.87 M17.44 M-3.37 M43.9 M93.81 M 151.78 M Free cash flow -8.62 M-8.89 M-10.24 M-10.57 M-18.04 M -47.73 M

News

Candel Stock: An Overlooked Late-Stage Biotech With Real Potential (NASDAQ:CADL)

Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade

Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript

Candel reports extended survival data for lung cancer therapy

H.C. Wainwright reiterates Candel Therapeutics stock rating at buy

Candel announces oral presentation on prostate cancer trial data

Candel Therapeutics stock falls on $100 million offering pricing

Why Is Candel Therapeutics Stock Falling Friday? - Candel Therapeutics (NASDAQ:CADL)

New Strong Sell Stocks for January 20th

Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday - Candel Therapeutics (NASDAQ:CADL), Centene (NYSE:CNC)

Candel Therapeutics stock price target raised to $14 by Freedom Capital

Candel Therapeutics to present phase 3 prostate cancer trial data at SITC